Maha Othman and Marc Carrier
May 10, 2025, 06:35
Maha Othman: Pleasure to Interview the Brilliant Dr. Marc Carrier at Our Latest Thrombosis Canada Clot Conversation Podcast
Professor Maha Othman, Co-Chairman SSC on Disseminated intravascular coagulopathy at International Society on Thrombosis and Haemostasis, shared a post on X:
“Pleasure to interview the brilliant Dr. Marc Carrier at our latest Thrombosis Canada clot conversation podcast. Extended anticoagulation with reduced-dose apixaban is noninferior to full-dose; preventing recurrent VTE in cancer patients while resulting in less bleeding.”
Quoting Thrombosis Canada‘s post:
“New study, new standard? Reduced-dose apixaban may change the game in cancer-associated thrombosis. Dr. Carrier explains why.
Listen here.”
Find more on Hemostasis Today.
-
Oct 9, 2026, 11:06Nobles Green: How siRNA Therapy Helps the Body Form Stronger Clots
-
Oct 9, 2026, 10:53Switching From Emicizumab to Denecimig in Hemophilia A – Rare Disease Advisor
-
Oct 9, 2026, 10:40What New U.S. Data Reveal About GT – Glanzmann’s Research Foundation
-
Oct 9, 2026, 10:32Anjali Pandey: The Morphologic Clues to MDS With del(5q)
-
Oct 9, 2026, 10:13Reza Shojaei: 5 Leadership Responsibilities for a Sustainable Plasma Ecosystem
-
Oct 9, 2026, 08:38Johannes Gratz: Perioperative Care in Factor VII Deficiency – Treating the Patient, Not the Number
-
Oct 9, 2026, 08:28Ghanim Fajish: Vascular Cells May Retain a Prothrombotic Memory of Oxidative Stress
-
Oct 9, 2026, 07:43Mehmet Cilingiroglu: The First Diagnosis of Coronary Thrombosis in a Living Patient
-
Oct 9, 2026, 07:21Federico Ravaioli: 40 kPa Spleen Stiffness May Help Avoid Endoscopy in Chronic PVT